 Hoth Therapeutics, Inc. Hoth or the Company NASDAQ: HOTH, a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 45-day option to purchase up to an additional 15 percent 15 of the number of shares of common stock sold in the offering solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 